Key result
RDN in resistant hypertension linked to ~13 mm Hg office SBP reduction at 12 months.
Why the study?
The efficacy of percutaneous renal sympathetic denervation in patients with true-resistant hypertension was assessed in a newly established network of Polish centres.
Does percutaneous renal sympathetic denervation reduce blood pressure and improve glycaemic control in patients with true resistant hypertension?
Observational (n=44)
Yes
Does percutaneous renal sympathetic denervation reduce blood pressure and improve glycaemic control in patients with true resistant hypertension?
Renal sympathetic denervation provides moderate blood pressure reduction in true resistant hypertension, with diabetes and baseline glucose predicting better response and potential improvements in glycaemic control.
Answers are grounded in this paper and cite their sources.
May support adjunctive use in resistant hypertension; leaves open outcome benefits pending randomized trials.
BACKGROUND AND AIM: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry). METHODS AND RESULTS: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure (SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were -23.8/-10.0, -12.5/-4.6, and -12.6/-6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4-66.5, p < 0.05). Mean 24-h SBP change was -8.3 mm Hg at 6 months and -4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04-1.48, p < 0.05). At 12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01-24.1, p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08-2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose was found as compared to the non-responders (-45.8 vs. -7.7 mg/dL, p < 0.005). CONCLUSIONS: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable positive impact of RDN on glycaemic control.
No takes yet. Share an insight, caveat, or question.
Kądziela et al. (2016) conducted an observational in True resistant hypertension (n=44). Percutaneous renal sympathetic denervation was evaluated on Mean reduction of office systolic blood pressure at 12 months. Percutaneous renal sympathetic denervation in patients with true resistant hypertension resulted in a mean office systolic/diastolic blood pressure reduction of 12.6/6.1 mm Hg at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: